Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLG-T-01: Up-Front ASCT in PTCL
NCT00791947Phase 2Completed
- Sponsor
- Aarhus University
- Start
- Oct 2001
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, etoposide, prednisone and 3 more in peripheral T-cell lymphoma (PTCL), sponsored by Aarhus University. Primary endpoint: Time to Treatment Failure at 5 years. Started Oct 2001; status: completed.
02
Drugs
cyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionetoposideprednisone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00791947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791947.